Published in
American Society of Hematology, Blood Advances, 7(6), p. 2427-2433, 2022
DOI: 10.1182/bloodadvances.2021005616
Links
Tools
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Journal article published in 2022 by
Alessandro Busca 
,
Jon Salmanton-García ,
Paolo Corradini ,
Francesco Marchesi ,
Alba Cabirta ,
Roberta Di Blasi ,
Remy Dulery ,
Sylvain Lamure ,
Francesca Farina ,
Barbora Weinbergerová ,
Josip Batinić ,
Anna Nordlander,
Alberto López-García ,
Ľuboš Drgoňa ,
Ildefonso Espigado-Tocino
and other authors.
,
Jon Salmanton-García ,
Paolo Corradini ,
Francesco Marchesi ,
Alba Cabirta ,
Roberta Di Blasi ,
Remy Dulery ,
Sylvain Lamure ,
Francesca Farina ,
Barbora Weinbergerová ,
Josip Batinić ,
Anna Nordlander,
Alberto López-García ,
Ľuboš Drgoňa ,
Ildefonso Espigado-Tocino
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.